Metabolic phenotyping combined with transcriptomics metadata fortifies the diagnosis of early-stage Hepatocellular carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Alpha-fetoprotein (AFP) has low sensitivity for early hepatocellular carcinoma (eHCC) detection. A new panel of serum metabolites combined with AFP significantly improves eHCC diagnosis accuracy.
Area Of Science
- Biomarker Discovery
- Metabolomics
- Hepatocellular Carcinoma (HCC) Research
Background
- Alpha-fetoprotein (AFP) exhibits low sensitivity for early hepatocellular carcinoma (eHCC) surveillance.
- There is a critical need for sensitive, blood-based biomarkers for eHCC detection.
Purpose Of The Study
- To identify a panel of serum metabolites as noninvasive diagnostic indicators for eHCC.
- To evaluate the diagnostic performance of a combined metabolite panel and AFP model.
Main Methods
- Serum samples from normal controls (NC), cirrhosis patients, and eHCC patients were analyzed using four metabolomic platforms.
- A meta-analysis of eHCC transcriptomic datasets was integrated with metabolic findings.
- A diagnostic model was developed incorporating a panel of 11 key metabolites and AFP.
Main Results
- Ninety-four metabolites significantly correlated with disease progression.
- Integrated analysis highlighted metabolic pathways including bile acid biosynthesis and amino acid metabolism.
- The combined metabolite panel and AFP model achieved 81.8% accuracy, significantly outperforming AFP alone (45.4%).
Conclusions
- Circulating metabolite panels show significant promise for the diagnosis of eHCC.
- The combined metabolite and AFP approach offers enhanced diagnostic accuracy for eHCC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.